Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Appoints Dr. Jyrki Mattila as Chief Business Officer

SALT LAKE CITY, May 18, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the appointment of Jyrki Mattila, M.D., Ph.D., M.B.A to the newly...
May 11, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Announces Presentation of Additional LPCN 1021 Clinical Data at American Urological Association Annual Meeting

SALT LAKE CITY, May 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that additional data from its ongoing Study of Oral Androgen...
May 07, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Announces Financial and Operational Results for the First Quarter of 2015

SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2015, as well as...
April 30, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Announces Completion of LPCN 1021, Oral Testosterone, Phase 3 Clinical Trial

SALT LAKE CITY, April 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient visit in the safety assessment...
April 29, 2015 16:38 ET | Source: Lipocine Inc.

Lipocine Announces Closing of $34.8 Million Common Stock Offering

SALT LAKE CITY, April 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the closing of an underwritten public offering of 5,347,500 shares...
April 29, 2015 16:00 ET | Source: Lipocine Inc.

Lipocine Prices $30.2 Million Public Offering of Common Stock

SALT LAKE CITY, April 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000...
April 24, 2015 08:30 ET | Source: Lipocine Inc.

Lipocine Prices $30.2 Million Public Offering of Common Stock

SALT LAKE CITY, April 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000...
April 23, 2015 16:00 ET | Source: Lipocine Inc.

Lipocine Announces Proposed Public Offering of Common Stock

SALT LAKE CITY, April 23, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its common...
April 10, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Announces Presentation of Additional LPCN 1021 Clinical Data at American Society of Andrology 40th Annual Conference

SALT LAKE CITY, April 10, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced that additional data from its ongoing Study of Oral Androgen...
March 24, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Announces Results From Pre-NDA Meeting for LPCN 1021, an Oral Testosterone Product Candidate

SALT LAKE CITY, March 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has completed its pre-New Drug Application ("NDA") meeting...